Scientists Calculated How Much Meat You Can Sustainably Eat in a Week
When it comes to eating meat, it sometimes seems impossible to strike a balance between doing the right thing for your body, and for the planet. Now, a team of environmental scientists has calculated a sweet spot that we can actually write on our shopping lists.
"Most people now realize that we should eat less meat for both environmental and health reasons. But it's hard to relate to how much 'less' is and whether it really makes a difference in the big picture," says lead author Caroline Gebara, an environmental scientist at the Technical University of Denmark.
That's why she and her team calculated a tangible figure – 255 grams (9 ounces) of poultry or pork per week – that people can factor into stocking their fridges.
That's roughly two chicken breasts. It's also six to ten times less meat than the average US or European citizen ate in 2021.
And the study suggests red meat – especially beef – cannot be part of an environmentally sustainable diet. That's probably because a lot of land must be cleared to farm animals like cows and sheep, which then emit methane (a greenhouse gas 28 times more potent than CO2) and nitrous oxide (270 times more potent than CO2) through their waste and feed crops.
"Our calculations show that even moderate amounts of red meat in one's diet are incompatible with what the planet can regenerate of resources based on the environmental factors we looked at in the study," Gebara says.
"However, there are many other diets – including ones with meat – that are both healthy and sustainable."
Humans have been eating animals and their byproducts for at least 2.6 million years, and we're not going to stop any time soon. But our hunger for meat is, to put it lightly, a bit out of control.
The environmental footprint of our livestock comes largely from greenhouse gases emitted directly by the animals, damage to the land used to raise them, and the fuel burned in transporting them, turning them into meat, and getting that meat to our plates.
One study estimated that greenhouse gases could stabilize for 30 years if animal agriculture, as it exists today, was rapidly phased out. That's an unlikely scenario, but it gives a sense of the industry's impact on our world.
With all that in mind, Gebara and her team conducted literature reviews to identify constraints for both healthy diets – resulting in 32 key nutritional requirements – and ones which are environmentally sustainable – based on a number of key thresholds for planetary sustainability.
All this came together to form a model that identified the amounts of different kinds of foods an individual could eat, per week, without putting undue strain on the planet's resources.
"For example, our calculations show that it's possible to eat cheese if that is important to you, while at the same time having a healthy and climate-friendly diet," Gebara says. "The same is true for eggs, fish, and white meat, but the premise is of course that the rest of your diet is then relatively healthy and sustainable. But it doesn't have to be either-or."
Models like this can really oversimplify different people's dietary needs and personal circumstances, which the authors acknowledge. The food characteristics used for the nutritional aspects of this study are based on US data, so they're more of a proxy for high-income countries than globally representative.
It's also difficult to capture all the many and varied impacts that food systems have across the world in a study like this. The model also relies on impacts of food production across one year remaining consistent, which is not the case in the real world. Technologies can change environmental impacts of certain foods, so this model will need to be updated over time.
"Our study focused on the biophysical limits of human nutrient intake and environmental impacts, but overlooked other aspects such as accessibility, affordability, and cultural acceptance," the authors write.
"Achieving truly sustainable diets requires universal availability, which must be supported by policymakers at all levels."
This research was published in Nature Food.
'Game Changer': Hot New Tech Turns Forever Chemicals Into Valuable Resource
'Bad Omen': Ancient Pyramid in Mexico Collapsed Into A Pile of Rubble
Pet Dogs Are Great For Our Health But They Have a Dark Side Too

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next
Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that it will acquire European telehealth platform Zava. The acquisition grows Hims & Hers' presence in the U.K. and gives the company a foothold in Germany, France, and Ireland, marking the company's biggest international move to date. The terms of the deal weren't disclosed, but the translation is an all-cash one expected to close later this year. Hims & Hers stock was up over 17% Tuesday morning — and is up an astounding 165% year to date. The deal adds more than 1.3 million active users to the company's existing 2.4 million subscriber base and positions Hims & Hers to roll out its digital healthcare model in some of Europe's largest healthcare markets. Weight-loss drugs will likely be a central part of that expansion. Andrew Dudum, Hims & Hers' CEO, told The Financial Times that there's a 'huge opportunity' in obesity, noting that Zava already offers branded weight-loss treatments and has seen growing demand. Hims & Hers is perhaps best known in the U.S. for its direct-to-consumer offerings across categories such as hair loss, sexual health, and anxiety — but its compounded GLP-1 medications have become one of its fastest-growing offerings. The company, which recently struck a deal to offer Novo Nordisk's Wegovy, has been threading a regulatory needle: offering custom formulations to a 'meaningfully smaller group of patients,' as CEO Andrew Dudum put it to The Financial Times. With the Zava deal, similar offerings could be on the horizon for Europe. In the U.K., compounded medications can legally be dispensed under certain conditions, providing an opening for Hims & Hers' approach. Lower pharmaceutical prices and public health system constraints could accelerate adoption. And with U.S. compounding regulations tightening and the branded supply stabilizing, international expansion could create a path for further growth. This isn't Hims & Hers' first international foray — the company acquired London-based Honest Health in 2021 — but the Zava deal adds an established European presence and could position Hims & Hers to build a branded footprint in key European markets while leveraging Zava's infrastructure. 'Early traction in the U.K. gives us confidence that we can scale our platform globally,' Dudum said on his company's recent earnings call. Zava CEO and co-founder David Meinertz will remain on board as general manager of the international business, and the Zava brand will reportedly stay live for a few quarters before rebranding as Hims & Hers. Meinertz said the deal could help ease pressure on Europe's strained healthcare systems. 'The medications are priced more competitively than in the U.S., so more people can actually afford it, and we are seeing a huge demand,' Meinertz told CNBC. 'The demand is increasing with additional strains on the statutory systems that telehealth can alleviate.' Hims & Hers is betting on that growing pressure on national health systems. 'Whether in rural towns, vibrant cities, or remote communities across Europe, people battling widespread, often silent chronic conditions like obesity, depression, and more will have access to the personalized, high-quality care they deserve,' Dudum said in the company's press release. 'The demand for simpler, more personalized healthcare is universal.' For the latest news, Facebook, Twitter and Instagram. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Hims Stock Surges 180%--Now It's Betting Big on Europe's $100B Weight-Loss Market
Hims & Hers Health (NYSE:HIMS) is doubling down on the global obesity drug boom. The U.S.-based telehealth company just snapped up European rival Zava in a cash deal, opening the door to 1.3 million new patients across the UK, Ireland, Germany, and France. CEO Andrew Dudum called obesity a huge opportunity and believes the path forward lies in personalized carenot just mass prescriptions. With demand already running hot for weight-loss treatments not covered by public healthcare, this acquisition could be Hims' ticket to scale its model far beyond U.S. borders. Warning! GuruFocus has detected 3 Warning Sign with HIMS. In the U.S., Hims built momentum by offering compounded versions of GLP-1 drugs like Wegovy and Zepbound during supply shortagesreplicas that mimicked the active ingredients but were tailored to individual needs. Even now, as shortages ease and compounding restrictions tighten, Hims hasn't exited the scene. Instead, it's pivoting toward more niche personalizations: lower doses, unique formulations, and side-effect-reducing combinations. That same playbook could be viable in the UK and Europe, where local rules still allow "specials"bespoke medications for patients with unique clinical needs. And here's the bigger picture: Hims isn't trying to replace branded drugsit's becoming the neutral platform that offers both. The company recently inked a deal with Novo Nordisk to sell Wegovy directly and expects more collaborations. Think of it like Switzerland: impartial, adaptive, and quietly positioning itself at the center of a lucrative market shift. With shares already up nearly 180% over the past year, investors could be looking at a business that's just getting startedespecially as Europe becomes its next frontier. This article first appeared on GuruFocus.
Yahoo
3 hours ago
- Yahoo
Hims Stock Surges 180%--Now It's Betting Big on Europe's $100B Weight-Loss Market
Hims & Hers Health (NYSE:HIMS) is doubling down on the global obesity drug boom. The U.S.-based telehealth company just snapped up European rival Zava in a cash deal, opening the door to 1.3 million new patients across the UK, Ireland, Germany, and France. CEO Andrew Dudum called obesity a huge opportunity and believes the path forward lies in personalized carenot just mass prescriptions. With demand already running hot for weight-loss treatments not covered by public healthcare, this acquisition could be Hims' ticket to scale its model far beyond U.S. borders. Warning! GuruFocus has detected 3 Warning Sign with HIMS. In the U.S., Hims built momentum by offering compounded versions of GLP-1 drugs like Wegovy and Zepbound during supply shortagesreplicas that mimicked the active ingredients but were tailored to individual needs. Even now, as shortages ease and compounding restrictions tighten, Hims hasn't exited the scene. Instead, it's pivoting toward more niche personalizations: lower doses, unique formulations, and side-effect-reducing combinations. That same playbook could be viable in the UK and Europe, where local rules still allow "specials"bespoke medications for patients with unique clinical needs. And here's the bigger picture: Hims isn't trying to replace branded drugsit's becoming the neutral platform that offers both. The company recently inked a deal with Novo Nordisk to sell Wegovy directly and expects more collaborations. Think of it like Switzerland: impartial, adaptive, and quietly positioning itself at the center of a lucrative market shift. With shares already up nearly 180% over the past year, investors could be looking at a business that's just getting startedespecially as Europe becomes its next frontier. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data